News

Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.

Timothy Hembree, DO, PhD, discusses how patients and physicians have benefited from an AI-supported virtual care system implemented at Moffitt Cancer Center.

A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.

LOTIS-5 finds loncastuximab tesirine plus rituximab improves PFS and response rates in relapsed/refractory DLBCL vs R-GemOx.

A first-in-human trial of the antibody-drug conjugate is planned for later this year.

FDA greenlights eight May 2026 oncology approvals, debuting first PROTAC, expanding breast ADCs, and advancing biomarker-driven bladder cancer and rare blood cancers.

FDA clears US enrollment for ateganosine plus cemiplimab in third-line NSCLC, testing telomere-targeting therapy after checkpoint and chemo failure.

During a live event, Amit Mahipal, MD, and participants discussed how to recognize and manage immune-related adverse events arising from combination regimens for unresectable HCC.

These 5 noteworthy abstracts provide a deeper dive into the 2026 ASCO gastrointestinal cancers data.

FDA fast-tracks TER-2013, an oral AKT1-selective inhibitor, for HR+/HER2– advanced breast cancer with AKT/PI3K/PTEN alterations.

Learn how TMB, PD-L1, smoking, and tumor burden shape first-line lung cancer immunotherapy choices, including when to add chemo or CTLA-4.

FDA clears automated PD-L1 22C3 testing on Dako Omnis for 4 more tumors, streamlining labs and guiding Keytruda therapy decisions.

5 noteworthy abstracts from a deeper dive into the ASCO genitourinary cancers data.

The FDA approved Lupin and Natco’s generic eribulin mesylate for pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.

FDA approves Cavhanza, a nilotinib orally disintegrating tablet for adult Ph+ CML, enabling use with PPIs/H2RAs and meals for easier dosing.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

Tucatinib plus trastuzumab/pertuzumab continued to show benefit in patients with HER2+ breast cancer regardless of distinguishing disease features.

"The VIKTORIA-1 trial validates the PAM pathway as a molecular driver in hormone receptor–positive, HER2-negative advanced breast cancer, regardless of PIK3CA mutation status," said Sara Hurvitz, MD.

“The results from this phase 3 study support iza-bren as a new standard of care for patients with pretreated metastatic triple-negative breast cancer,” said Jiong Wu, MD, PhD.

"DISC-0974 treatment resulted in sustained hepcidin and serum iron, regardless of concomitant JAKi therapy or baseline transfusion requirement,” said Naseema Gangat, MBBS.

FDA fast-tracks oral SERD giredestrant for early ER+/HER2- breast cancer after phase 3 shows 30% fewer invasive recurrences.

"Sacituzumab govitecan plus pembrolizumab [led to] improvement in PFS2...despite the crossover design of the trial," said Eleonora Teplinsky, MD.

A review of top ASCO abstracts with the potential to change everyday oncology practice.

"This is one of very few studies in advanced squamous NSCLC that has shown median survival beyond 2 years," said Shun Lu, MD, PhD.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

Five-year KEYNOTE-942 data show intismeran plus pembrolizumab delivers durable improvements in RFS and DMFS in high-risk resected melanoma.

“In this interim analysis…the response rate with the zelenectide pevedotin and pembrolizumab [was] promising, supporting its benefit-risk profile and supporting…the optimized dosing," said Yohann Loriot, MD, PhD.